|Mr. Robert W. Duggan||Exec. Chairman||N/A||N/A||1945|
|Mr. Kevin Danahy||Chief Exec. Officer||393.25k||N/A||1971|
|Mr. Darrin R. Uecker||CTO & Director||487.24k||N/A||1966|
|Mr. Mitchell E. Levinson||Chief Strategy Officer||361.34k||N/A||1960|
|Dr. Richard Nuccitelli Ph.D.||Chief Science Officer||N/A||N/A||N/A|
|Mr. Kenneth B. Stratton Esq., J.D.||Gen. Counsel & Corp. Sec.||N/A||N/A||1969|
|Ms. Patty Perla||VP of HR||N/A||N/A||N/A|
|Mr. David Danitz||Sr. VP of Engineering||N/A||N/A||N/A|
|Dr. Gansevoort Dunnington M.D.||Chief Medical Officer||N/A||N/A||N/A|
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. The company was incorporated in 2014 and is headquartered in Hayward, California.
Pulse Biosciences, Inc.’s ISS Governance QualityScore as of September 1, 2023 is 7. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 6; Compensation: 9.